G. A. A. Burke Et Al. , "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy," LEUKEMIA , vol.34, no.8, pp.2271-2275, 2020
Burke, G. A. A. Et Al. 2020. Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. LEUKEMIA , vol.34, no.8 , 2271-2275.
Burke, G. A. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R. E., ... Kabickova, E.(2020). Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. LEUKEMIA , vol.34, no.8, 2271-2275.
Burke, G. Et Al. "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy," LEUKEMIA , vol.34, no.8, 2271-2275, 2020
Burke, G. A. Et Al. "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy." LEUKEMIA , vol.34, no.8, pp.2271-2275, 2020
Burke, G. A. A. Et Al. (2020) . "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy." LEUKEMIA , vol.34, no.8, pp.2271-2275.
@article{article, author={G. A. Amos Burke Et Al. }, title={Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy}, journal={LEUKEMIA}, year=2020, pages={2271-2275} }